6,6-dimethyl-2-phenyl-1-pyridin-3-yl-5,7-dihydro-4H-indol-4-ol | 96757-55-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 6,6-dimethyl-2-phenyl-1-pyridin-3-yl-5,7-dihydro-4H-indol-4-ol
• CAS: 96757-55-0
• 化学式: C₂₁H₂₂N₂O
• 分子量: 318.418
• InChiKey: YTTPRIYCMBVMIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-phenacyldimedone 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 6,6-dimethyl-2-phenyl-1-pyridin-3-yl-5,7-dihydro-4H-indol-4-ol
  参考文献：
  名称：

  Nagarajan, K.; Talwalker, P. K.; Shah, R. K., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1985, vol. 24, p. 98 - 111

  摘要：

  DOI：

文献信息

• COMPOUNDS FOR ALZHEIMER'S DISEASE
  申请人：Manfredi John

  公开号：US20130261118A1

  公开（公告）日：2013-10-03

  The present disclosure relates to novel indole and tetrahydroindole core compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport).

  本公开涉及新型吲哚和四氢吲哚核心化合物，可用于治疗与囊泡运输缺陷（例如轴突运输）相关的疾病。
• NAGARAJAN, K.;TALWALKER, P. K.;SHAH, R. K.;MEHTA, S. R.;NAYAK, G. V., INDIAN J. CHEM., 1985, 24, N 1, 98-111
  作者：NAGARAJAN, K.、TALWALKER, P. K.、SHAH, R. K.、MEHTA, S. R.、NAYAK, G. V.

  DOI：——

  日期：——
• COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
  申请人：Manfredi, John

  公开号：EP2970118A1

  公开（公告）日：2016-01-20
• US9216966B2
  申请人：——

  公开号：US9216966B2

  公开（公告）日：2015-12-22
• [EN] COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE TROUBLES NEUROLOGIQUES
  申请人：MANFREDI JOHN

  公开号：WO2014164222A1

  公开（公告）日：2014-10-09

  The invention provides compounds with the structure of Formula I: wherein R6-R10, R6'-R9', R20 and R21 are as defined in the claims, useful in methods of treating neurodegenerative diseases or disorders associated with compromised axonal function. The present disclosure provides compounds, compositions and methods of synthesizing compounds that are effective against neurodegenerative disorders, including their action as neurotrophic and axonotrophic agents. The present disclosure provides methods for the therapeutic treatment of neurodegenerative disorders, and methods of prophylaxis against neurodegenerative disorders.